Moderna, Inc. (MRNA) operating KPIs
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$221.72−1.04 (-0.47%)
Close on Oct 30, 2026Market cap $88.52BP/E –Yield –
KPIs
Operating metrics that drive Moderna's business
| Rentable area (sq ft) | Q2 26 | Q1 26 | Q3 25 | Q2 25 | Q1 25 | Q3 24 | Q2 24 | Q1 24 | Q3 23 | Q2 23 | Q1 23 | Q3 22 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cambridge leases | 462,000 | 462,000 | 462,000 | 462,000 | 462,000 | 667,000 | 667,000 | 276,000 | 292,000 | 292,000 | 292,000 | 261,000 | 0.0% |
Counts and sizes Moderna tags in the notes of its 10-K and 10-Q filings (XBRL), as of the end of each quarter. Breakdowns follow the company's own labels; at most 15 are shown per metric. A fuller KPI sheet built from earnings releases and presentations is on the way. See how companies compare on these metrics.